%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Cressey, T. R.
%A Harrison, L.
%A Achalapong, J.
%A Kanjanavikai, P.
%A Ayudhaya, O. P. N.
%A Liampongsabuddhi, P.
%A Siriwachirachai, T.
%A Putiyanun, C.
%A Suriyachai, P.
%A Tierney, C.
%A Salvadori, Nicolas
%A Chinwong, D.
%A Decker, Luc
%A Tawon, Y.
%A Murphy, T. V.
%A Ngo-Giang-Huong, Nicole
%A Siberry, G. K.
%A Jourdain, Gonzague
%A iTAP Study Team
%T Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus
%D 2018
%L fdi:010074806
%G ENG
%J Antimicrobial Agents and Chemotherapy
%@ 0066-4804
%K pregnancy ; tenofovir ; hepatitis B virus ; pharmacokinetics
%K THAILANDE
%M ISI:000451216800051
%N 12
%P e01686-18 [5 ]
%R 10.1128/aac.01686-18
%U https://www.documentation.ird.fr/hor/fdi:010074806
%> https://www.documentation.ird.fr/intranet/publi/2018/12/010074806.pdf
%V 62
%W Horizon (IRD)
%X We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC(0-24) was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.
%$ 052 ; 050